Shares of Absci Corp rocketed 19.5% to $7.10 on June 4, defying a lack of any confirmed company announcement and raising questions about whether insider-buying signals and biotech sector momentum can sustain a stock that had been sliding all week. Absci Pops 19% With No Headline to Show for It — Can Conference Buzz and a Short Squeeze Keep This AI Biotech Aloft?
Shares of Absci Corp surged 19.5% to $7.10 on June 4 without a single confirmed company announcement, snapping a week-long slide from $6.75 and raising a blunt question: what exactly are investors buying?
• The Annual Meeting and Jefferies Presentation May Be Doing the Talking. Absci's 2026 Annual Meeting of Stockholders was scheduled for June 4 at 9:00 a.m. Eastern Time , and management presented at the Jefferies Global Healthcare Conference on June 3 . That one-two punch gave investors fresh management commentary right before the annual vote — enough to stoke buying in a thinly traded name. Leerink also initiated coverage with an Outperform rating this week, while BTIG launched with a Buy on May 22 , giving institutional buyers fresh justification to step in.
• A Quarter of the Stock Is Sold Short, and Shorts Are Trapped. Short interest stands at roughly 35.1 million shares, representing 25.9% of the stock's available float . Based on average daily volume of about 5.3 million shares, it would take roughly six days for short sellers to unwind . In plain terms, a huge number of traders are betting against Absci, and a sharp up-day forces some of them to buy shares to limit losses — which pushes the price even higher. Today's jump has the hallmarks of exactly that dynamic.
• The Fundamentals Remain Paper-Thin. Absci posted just $215,000 in Q1 2026 revenue, missing the $1.43 million forecast by nearly 85% . Trailing-twelve-month net losses sit at $115.2 million . The company is pre-revenue in any meaningful sense, burning cash to advance its lead AI-designed antibody drug through early clinical trials for hair loss and endometriosis. Management says it has enough cash to operate into the first half of 2028 , but another capital raise — diluting existing shareholders — is almost certainly ahead.
• The Real Catalyst Is Still Months Away. Absci expects to report preliminary safety and blood-level data for its hair-loss drug in Q2 2026 , with clinical proof-of-concept data anticipated in the second half of 2026 . Fifteen analysts carry an average price target of $8.92, implying about 23% further upside . Until that data arrives, investors are trading on narrative, not numbers — and today's gap-up, fueled more by positioning mechanics than substance, could reverse just as violently.